Home Twitter

Out-licensing

In order to retain greater value for the Shareholders, Zealand intends to take development programs through to clinical proof of principle before partnering, unless attractive out-licensing opportunities arise earlier.

Contact person:

AMH_2012_100x100
Arvind M. Hundal
Senior Vice President and CBO
e-mail: amh@zealandpharma.com